Lisata Therapeutics Inc (LSTA)
Lisata Therapeutics, Inc. is a clinical-stage biotechnology company listed on the NASDAQ under the ticker LSTA. The company focuses on discovering, developing, and commercializing therapies for solid tumors and other diseases. Its lead investigational candidate, certepetide, is being evaluated in Phase 2 studies across several cancer indications, including metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer, and glioblastoma multiforme, in combination with a range of anti-cancer regimens. Incorporated in 1980, Lisata Therapeutics is headquartered in Basking Ridge, New Jersey.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LSTA
|
$1.03
|
4.1% Upside
|
Fair
|
$4
|
303.4% Upside
|
Bargain
|
Fair
|
0.0%
|
1.1x
|
89.3x
|
9.056 M
|
-1.763 M
|
0.0%
|
76.7%
|
-168.3
|
84.3%
|
